Nabi Biopharmaceuticals, NicVAX(R) , Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months

Nov. 7, 2007 - ... NicVAX(R) is an innovative and proprietary investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX(R) is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier. Therefore, NicVAX(R) blocks nicotine from reaching its receptors in the brain and prevents the highly-addictive pleasure sensation experienced by smokers and users of nicotine products... Nabi's Press Release -